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We report a case of disseminated M. genavense infec-
tion resulting from neutralizing anti–IFN-γ autoantibodies 
in the patient. M. genavense infection should be considered 
in the differential diagnosis of mycobacteria detected with 
AFB staining but not with culture, even in patients without 
known evidence of immunodeficiency. Adult-onset immu-
nodeficiency acquired by neutralizing anti–IFN-γ autoanti-
bodies, in addition to HIV infection, can lead to dissemi-
nated NTM infection.
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During an outbreak of Q fever in Germany, we identified 
an infected sheep flock from which animals were routinely 
used as a source for life cell therapy (LCT), the injection of 
fetal cells or cell extracts from sheep into humans. Q fever 
developed in 7 LCT recipients from Canada, Germany, and 
the United States.
Gram-negative intracellular bacteria (Coxiella burnetii) cause Q fever, a zoonotic disease usually subclinical 
in livestock and humans. Typically, human patients show 
signs and symptoms, such as fever, severe headache, nau-
sea, pneumonia, or hepatitis, 2-3 weeks after infection. 
Chronic Q fever develops in ≈1%–5% of patients (1).
On August 5, 2014, a local health department in the 
Federal State of the Rhineland Palatinate in southern 
Germany alerted the Federal State Agency for Consumer 
and Health Protection (FSACHP) (Landau, Germany) 
after detecting a cluster of 8 patients with pneumonia 
in a rural community during a 6-week period. The local 
health department and FSACHP started a joint outbreak 
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investigation to identify cases, find the source of the out-
break, and stop disease transmission.
On August 12, five of 8 patients tested by ELISA and 
immunofluorescence test (IFT) by the local health depart-
ment had results consistent with acute C. burnetii infection. 
The local health department issued a public health warning 
in the local media and advised anyone in the affected com-
munity with influenza-like symptoms or pneumonia in the 
past 4 months to be tested for Q fever by their general prac-
titioner. In addition, the department offered free testing to 
pregnant women and persons with cardiovascular risk fac-
tors (e.g., heart valve defects), irrespective of symptoms (2).
Case-patients were defined as persons who had phase 
II IgM or IgG titers for Q fever by ELISA or IFT in 2014. 
Data for these case-patients were entered into the German 
Electronic Surveillance System for Infectious Disease 
Outbreaks (3). Thirteen residential case-patients (6 men, 7 
women) who lived in the affected county (Bad Duerkheim) 
were identified; 11 reported symptoms compatible with Q 
fever, of whom 6 were hospitalized (Figure). Median age 
for residential case-patients was 50 (range 32–59) years for 
women and 44 (range 26–56) years for men.
Because all residential case-patients lived within 1.5 
km of a flock of 1,000 sheep, the FSACHP tested random 
samples from these sheep. Of 61 sheep tested, 25 were pos-
itive for C. burnetii by ELISA of serum samples and 2 by 
PCR of vaginal swab specimens. During the investigation, 
the local health department discovered that young rams and 
pregnant ewes in the flock had been used as donor animals 
for live cell therapy (LCT) at 2 medical facilities in a dis-
trict 10 km from the farm. LCT is injection of fetal cells or 
cell extracts from sheep into humans. The flock was banned 
for LCT production, and veterinary control measures (e.g., 
indoor housing and immunization of sheep) were initiated 
to stop transmission.
Staff members of LCT facilities were offered serologic 
testing by ELISA or IFT. Sixteen persons with occupational 
cases (3 men, 13 women) were reported; 10 showed onset 
of disease, and 2 were hospitalized (Figure). Median age 
for occupational case-patients was 48 (range 28–62) years 
for women and 45 (range 35–50) years for men.
LCT is an alternative treatment (without medical evi-
dence of effectiveness) that is marketed worldwide online. 
It consists of intramuscular injections of cell suspensions 
from fetal sheep to human recipients for rejuvenation (an-
ti-aging) and other ailments. Apart from national recipi-
ents, medical tourists from North America and Asia travel 
to Germany to receive injections. In August, the FSACHP 
was notified of a patient from Canada who received LCT 
injections on May 28, 2014, and became ill in June, be-
fore C. burnetii was detected in the asymptomatic donor 
sheep herd (4,5).
Newspaper coverage in October of the Q fever out-
break and the potential link to the LCT recipient from Can-
ada alerted an LCT recipient in Germany who had recov-
ered from a previously unidentified illness after receiving 
LCT in Rhineland Palatinate (4,6). The patient  became ill 
(fever, severe diarrhea, and fatigue) 1 day after receiving 
LCT injections on July 14, lost 9 kg, and was hospitalized 
for 10 days. She was positive for Q fever by IFT in October 
2014 and had a phase II IgG titer (1:65,536) that was higher 
than her phase I IgG titer (1:4,096), which indicated a re-
cent infection. She had no other contact with sheep or sheep 
products during her stay at the LCT facility or thereafter.
A pharmacovigilance report by the Paul Ehrlich Insti-
tut (Langen, Germany) indicated that LCT treatment was 
the probable cause of the Q fever (7). The county ordered 
both LCT facilities to advise all 830 LCT recipients treated 
since January 2014 to consult their general practitioner 
about their possible risk for Q fever. This advice prompted 
5 US citizens who received injections on May 30 in one of 
the clinics to be tested for Q fever. An investigation by the 
US Centers for Disease Control and Prevention (Atlanta, 
GA, USA) identified recent Q fever in all 5 patients (phase 
II IgG titers <1:65,536 at 2–6 months postinjection) (5).
Several facilities offer LCT in Germany, although the 
federal ministry of health recently released an assessment 
stating that the use of LCT is unsafe (8). Therefore, prac-
titioners worldwide should be informed that working at an 
LCT clinic or receiving LCT injections should be consid-
ered potential risk factors for Q fever.
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Figure. Residential (n = 11), occupational (n = 10), and recipient 
(n = 1) cases of Q fever related to live cell therapy (LCT), by week 
of symptom onset compatible with Q fever, Rhineland-Palatinate, 
Germany, 2014
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We identified 3 novel and distinct avulaviruses from Gentoo 
penguins sampled in Antarctica. We isolated these viruses 
and sequenced their complete genomes; serologic assays 
demonstrated that the viruses do not have cross-reactivity 
between them. Our findings suggest that these 3 new vi-
ruses represent members of 3 novel avulavirus species.
Avian paramyxovirus (APMV) belongs to the genus Avulavirus, family Paramyxoviridae. There are 13 
recognized Avulavirus species, each with 1 member, called 
avian paramyxovirus 1–13 (APMV-1–APMV-13) (1). A 
putative APMV-14 also has been recently described but not 
yet formally recognized (2).
In the past decade, APMV-10 through APMV-14 have 
been reported because of the intensification of surveillance 
of avian influenza A viruses (3–6). Most of the avulaviruses 
have been detected in wild birds associated with mild or no 
clinical disease; only Newcastle disease virus (a strain of 
APMV-1), APMV-2, and APMV-3 might cause substantial 
disease in poultry (7). Previous studies have described the 
presence of APMV-1, APMV-3, APMV-7, APMV-8, and 
other as-yet uncharacterized avulaviruses in Antarctic pen-
guins (8). As a part of avian influenza surveillance expedi-
tions in Antarctica during 2014–2016, we identified 3 novel 
avulaviruses in Gentoo penguins.
Cloacal, fecal, and serum samples were collected 
from Gentoo penguins (Pygoscelis papua) and Adélie pen-
guins (P. adeliae), at 7 Antarctic locations (online Tech-
nical Appendix Figure 1, https://wwwnc.cdc.gov/EID/
article/23/7/17-0054-Techapp1.pdf) during 2014–2016. 
Diagnostic tests, virus isolation, and serologic assays con-
firmed the identity of these paramyxoviruses (online Tech-
nical Appendix).
We successfully isolated virus from 12 cloacal sam-
ples from Gentoo penguins on Kopaitic Island; these vi-
ruses showed positive hemagglutination titers ranging 
from 4 to 128 hemagglutination units. From these 12 iso-
lates, only 5 were further confirmed by reverse transcrip-
tion PCR and Sanger sequencing (9), suggesting the pres-
ence of new avulaviruses. All PCR-positive isolates were 
pooled and submitted for next-generation sequencing by 
using MiSeq 250 paired cycle run (Illumina, San Diego, 
CA, USA) (10).
By using next-generation sequencing, we obtained 
the genomic sequences of 3 novel avulaviruses that were 
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